Abstract:HomeCirculationVol. 137, No. 17Response by Hu et al to Letters Regarding Article, “Platelets Express Activated P2Y12 Receptor in Patients With Diabetes Mellitus” Free AccessLetterPDF/EPUBAboutView PDFView EPUBSections ToolsAdd to favoritesDownload citationsTrack citationsPermissions ShareShare onFacebookTwitterLinked InMendeleyReddit Jump toFree AccessLetterPDF/EPUBResponse by Hu et al to Letters Regarding Article, “Platelets Express Activated P2Y12 Receptor in Patients With Diabetes Mellitus” Liang Hu, PhD, Zhiyong Qi, MD, Si Zhang, MD, PhD, Xinping Luo, MD, PhD, Satya P. Kunapuli, PhD, Hongying Ye, MD, PhD and Zhongren Ding, MD, PhD Liang HuLiang Hu Key Laboratory of Metabolism and Molecular Medicine, Ministry of Education, Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Fudan University, People’s Republic of China (L.H., S.Z., Z.D.). Search for more papers by this author , Zhiyong QiZhiyong Qi Division of Cardiovascular Disease (Z.Q., X.L.) Search for more papers by this author , Si ZhangSi Zhang Key Laboratory of Metabolism and Molecular Medicine, Ministry of Education, Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Fudan University, People’s Republic of China (L.H., S.Z., Z.D.). Search for more papers by this author , Xinping LuoXinping Luo Division of Cardiovascular Disease (Z.Q., X.L.) Search for more papers by this author , Satya P. KunapuliSatya P. Kunapuli Huashan Hospital, Fudan University, People’s Republic of China. Sol Sherry Thrombosis Research Center Professor of Physiology and Pharmacology Lewis Katz School of Medicine, Temple University, Philadelphia, PA (S.P.K.). Search for more papers by this author , Hongying YeHongying Ye Division of Endocrinology and Metabolism (H.Y.) Search for more papers by this author and Zhongren DingZhongren Ding Key Laboratory of Metabolism and Molecular Medicine, Ministry of Education, Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Fudan University, People’s Republic of China (L.H., S.Z., Z.D.). Search for more papers by this author Originally published24 Apr 2018https://doi.org/10.1161/CIRCULATIONAHA.117.032709Circulation. 2018;137:1877–1878In Response:We appreciate the thoughtful comments from He and Li. We are grateful that they have given our paper such careful attention and were prompted to share their interesting and stimulating ideas on our work.1We think the platelets P2Y12 expression is dynamic and related to blood glucose level, as we found the age-dependent platelet P2Y12 increase correlates well with blood glucose increase in Goto-Kakizaki diabetic rats (see Figure 3F1). He and Li raised an important question: Do hypoglycemic drugs have effects on the expression of platelet P2Y12 receptor? We did not check whether platelet P2Y12 receptor expression would decrease with better glucose control. Whether hypoglycemic drugs have effect on platelet P2Y12 expression or platelet hyperactivity is not clear and further studies are needed.We thank He and Li for pointing out the potential clinic use of P2Y12 inverse agonist in patients with diabetes mellitus. AR-C78511 was first developed by AstraZeneca; pharmacodynamic and pharmacokinetic of AR-C78511 have not been previously reported. Using platelets from patients with diabetes mellitus and 2 kinds of thrombosis models of diabetic rats, we show superior antiplatelet and antithrombotic effects of AR-C78511 as a P2Y12 inverse agonist over cangrelor. The adverse effects, including bleeding risk, are not clear, compared with other stronger antiplatelet drugs. Ticagrelor, which inhibits platelet activation more effectively than clopidogrel and prasugrel in patients with diabetes mellitus,2,3 was recently reported to be a potent P2Y12 receptor inverse agonist.4 Considering the constitutive activation of P2Y12 receptor in patients with diabetes mellitus, P2Y12 receptor antagonists with potent inverse agonist activity may have therapeutic advantage for antiplatelet therapy.5 As a potent inverse agonist with superior antiplatelet and antithrombotic activity, AR-C78511 may deserve further development for clinical use in diabetes mellitus.Increased net adverse clinical and cerebral events and major bleeding have been reported in patients receiving ticagrelor compared with clopidogrel.6 Individualized antiplatelet using P2Y12 receptor antagonist with inverse agonist activity such as ticagrelor and AR-C78511, based on platelet P2Y12 expression level, may minimize bleeding risk while maintaining the superior antithrombotic efficacy.We thank Gong et al for their interest in our paper. One of our major findings in this paper is that platelets in diabetes mellitus have increased P2Y12 receptor expression, supported by patient samples, animal models, and cell line studies. We refer Gong et al to a recent paper from Fejes et al,7 which demonstrates that platelets from patients with diabetes mellitus express significantly higher P2Y12. They also demonstrated enhanced P2Y12 expression in Meg-01 cells treated with high glucose. These results are consistent with our findings. It is possible that the P2Y12 expression increases in the other conditions mentioned by Gong et al. We predict that whenever the P2Y12 expression increases in a disease state, the inverse agonist, such as AR-C78511 or ticagrelor, would be more effective than a neutral antagonist, such as cangrelor. Finally, we do not agree with the notion that the first 2 to 4 mL of the blood draw would cause platelet activation, as these are comparative studies and would have occurred in both patient and normal samples. Such risk of activation is known to be minimal, as the blood draw methodology has been standardized over several decades to minimize such risk.DisclosuresNone.Footnoteshttp://circ.ahajournals.orgReferences1. Hu L, Chang L, Zhang Y, Zhai L, Zhang S, Qi Z, Yan H, Yan Y, Luo X, Zhang S, Wang Y, Kunapuli SP, Ye H, Ding Z. Platelets express activated P2Y12 receptor in patients with diabetes mellitus.Circulation. 2017; 136:817–833. doi: 10.1161/CIRCULATIONAHA.116.026995.LinkGoogle Scholar2. Mangiacapra F, Panaioli E, Colaiori I, Ricottini E, Lauria Pantano A, Pozzilli P, Barbato E, Di Sciascio G. Clopidogrel versus ticagrelor for antiplatelet maintenance in diabetic patients treated with percutaneous coronary intervention: results of the CLOTILDIA study (Clopidogrel High Dose Versus Ticagrelor for Antiplatelet Maintenance in Diabetic Patients).Circulation. 2016; 134:835–837. doi: 10.1161/CIRCULATIONAHA.116.023743.LinkGoogle Scholar3. Franchi F, Rollini F, Aggarwal N, Hu J, Kureti M, Durairaj A, Duarte VE, Cho JR, Been L, Zenni MM, Bass TA, Angiolillo DJ. Pharmacodynamic comparison of prasugrel versus ticagrelor in patients with type 2 diabetes mellitus and coronary artery disease: the OPTIMUS (Optimizing Antiplatelet Therapy in Diabetes Mellitus)-4 study.Circulation. 2016; 134:780–792. doi: 10.1161/CIRCULATIONAHA.116.023402.LinkGoogle Scholar4. Aungraheeta R, Conibear A, Butler M, Kelly E, Nylander S, Mumford A, Mundell SJ. Inverse agonism at the P2Y12 receptor and ENT1 transporter blockade contribute to platelet inhibition by ticagrelor.Blood. 2016; 128:2717–2728. doi: 10.1182/blood-2016-03-707844.CrossrefMedlineGoogle Scholar5. Parker WA, Storey RF. Ticagrelor: agonising over its mechanisms of action.Blood. 2016; 128:2595–2597. doi: 10.1182/blood-2016-10-743930.CrossrefMedlineGoogle Scholar6. Zocca P, van der Heijden LC, Kok MM, Löwik MM, Hartmann M, Stoel MG, Louwerenburg JW, de Man FHAF, Linssen GCM, Knottnerus IL, Doggen CJM, van Houwelingen KG, von Birgelen C. Clopidogrel or ticagrelor in acute coronary syndrome patients treated with newer-generation drug-eluting stents: CHANGE DAPT.EuroIntervention. 2017; 13:1168–1176. doi: 10.4244/EIJ-D-17-00634.CrossrefMedlineGoogle Scholar7. Fejes Z, Póliska S, Czimmerer Z, Káplár M, Penyige A, Gál Szabó G, Beke Debreceni I, Kunapuli SP, Kappelmayer J, Nagy B. Hyperglycaemia suppresses microRNA expression in platelets to increase P2RY12 and SELP levels in type 2 diabetes mellitus.Thromb Haemost. 2017; 117:529–542. doi: 10.1160/TH16-04-0322.CrossrefMedlineGoogle Scholar Previous Back to top Next FiguresReferencesRelatedDetails April 24, 2018Vol 137, Issue 17 Advertisement Article InformationMetrics © 2018 American Heart Association, Inc.https://doi.org/10.1161/CIRCULATIONAHA.117.032709PMID: 29685940 Originally publishedApril 24, 2018 PDF download Advertisement

Response to Letter Regarding Article, “platelet Expression Profiling and Clinical Validation of Myeloid-Related Protein-14 As a Novel Determinant of Cardiovascular Events”

Letter by Jin-shan and Xue-bin Regarding Article, “platelets Express Activated P2Y 12 Receptor in Patients with Diabetes Mellitus”

Response to Letter Regarding Article, “CYP2C19 Polymorphisms and Antiplatelet Effects of Clopidogrel in Acute Ischemic Stroke in China”

Response by Hu Et Al to Letters Regarding Article, “platelets Express Activated P2Y 12 Receptor in Patients with Diabetes Mellitus”

Letter by Jin-shan and Xue-bin Regarding Article, “coronary Plaque Characterization in Psoriasis Reveals High-Risk Features That Improve after Treatment in a Prospective Observational Study”

Associations Between Genetic Variation in the Targets of Low-Density Lipoprotein-Lowering Drugs and Rheumatoid Arthritis

Unraveling the transcriptomic landscape of platelets: RPs vs. MPs in CCS patients

Perivascular Fat Attenuation Index Mapping and Tracking Immunoglobulin G4-Related Coronary Arteritis

Response by Xu Et Al to Letter Regarding Article, “Branched-Chain Amino Acid Catabolism Promotes Thrombosis Risk by Enhancing Tropomodulin-3 Propionylation in Platelets”

Factors that modulate platelet reactivity as measured by 5 assay platforms in 3429 individuals

A Platelet Reactivity ExpreSsion Score derived from patients with peripheral artery disease predicts cardiovascular risk

Lipoprotein-Associated Phospholipase A(2) And Risk Of Coronary Disease, Stroke, And Mortality: Collaborative Analysis Of 32 Prospective Studies

Introducing a Novel Biophysical Platelet Function Panel to Investigate Disorders of Primary Hemostasis and Bleeding of Unknown Cause

Abstract 16835: Plasma Proteomics and Risk of Incident HFpEF and HFrEF: The Atherosclerosis Risk in Communities Study

Effects of Randomized Treatment With Icosapent Ethyl and a Mineral Oil Comparator on Interleukin-1β, Interleukin-6, C-Reactive Protein, Oxidized Low-Density Lipoprotein Cholesterol, Homocysteine, Lipoprotein(a), and Lipoprotein-Associated Phospholipase A2: A REDUCE-IT Biomarker Substudy

Abstract 13031: Real World Outcomes of Prognostic Value of Platelet Function Testing for Five-Year Ischemic Events in Patients Undergoing Percutaneous Coronary Intervention: A Large-Scale Cohort Study

Plasma Proteomics to Identify Drug Targets for Ischemic Heart Disease

A genome- and phenome-wide association study to identify genetic variants influencing platelet count and volume and their pleiotropic effects

Soluble Platelet Release Factors as Biomarkers for Cardiovascular Disease

Platelet FcγRIIa as a Marker of Cardiovascular Risk After Myocardial Infarction

The role of P2Y12 in cardiovascular disease beyond atherothrombosis: P2Y12 signaling promotes emergency hematopoiesis after myocardial infarction